anti-CEA CAR-T cells + gemcitabine + nab-paclitaxel

This is a combination regimen consisting of anti-CEA chimeric antigen receptor T cells (anti-CEA CAR-T cells), gemcitabine, and nab-paclitaxel. - **Anti-CEA CAR-T cells** are autologous T lymphocytes genetically engineered to express a chimeric antigen receptor targeting carcinoembryonic antigen (CEA), a tumor-associated antigen commonly overexpressed in several solid tumors such as colorectal, pancreatic, and some breast cancers[1][2][3]. By redirecting T cell specificity to CEA, these cells mediate direct cytotoxicity against CEA-positive tumor cells. - **Gemcitabine** is a nucleoside analog small molecule chemotherapy that inhibits DNA synthesis, leading to apoptosis of proliferating tumor cells. - **Nab-paclitaxel** is an albumin-bound formulation of paclitaxel, a microtubule inhibitor used in various solid tumors. This regimen is being explored primarily in the treatment of advanced, CEA-positive solid tumors (notably pancreatic adenocarcinoma and breast cancer) as a multimodal anti-cancer therapy aiming to combine the benefits of targeted immunotherapy with cytotoxic chemotherapy to overcome resistance mechanisms associated with solid tumors and to enhance overall efficacy[1][2][3].